The HR deficiency occurring as a result of LMO2 expression rendered T-ALL cells more sensitive to PARP inhibition (using olaparib), both as a single agent as well as in combination with doxorubicin (130). This evidence concerns the gene PARP1 and acute lymphoblastic leukemia.